Screening of large numbers of Streptococcus pneumoniae isolates for mutations associated with fluoroquinolone resistance using an oligonucleotide probe assay

FEMS Microbiology Letters

Volumn 217, Issue 2, 2002, Pages 219-224

  Davies, Todd A ^a   Goldschmidt, Raul ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Fluoroquinolone resistant; Oligonucleotide probe; Streptococcus pneumoniae

Indexed keywords

DNA BASE; OLIGONUCLEOTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRAMETHYLAMMONIUM CHLORIDE;

ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA BASE COMPOSITION; DRUG RESISTANCE; MELTING POINT; NONHUMAN; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TEMPERATURE;

ANTI-INFECTIVE AGENTS; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; MUTATION; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE PROBES; STREPTOCOCCUS PNEUMONIAE;

STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037126673     PISSN: 03781097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1097(02)01087-X     Document Type: Article

References (10)

1. Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Pankuch G.A., Appelbaum P.C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study. Antimicrob. Agents Chemother. 43:1999;1901-1908.
2. Sahm D.F., Karlowsky J.A., Kelly L.J., Critchley I.A., Jones M.E., Thornsberry C., Mauriz Y., Kahn J. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 45:2001;1037-1042.
3. Pan X.-S., Ambler J., Mehtar S., Fisher L.M. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:1996;2321-2326.
4. Barry A.L., Brown S.D., Fuchs P.C. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 43:1999;428-429.
5. Davies T.A., Kelly L.M., Pankuch G.A., Credito K.L., Jacobs M.R., Appelbaum P.C. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob. Agents Chemother. 44:2000;304-310.
6. Jones M.E., Sahm D.F., Martin N., Scheuring S., Heisig P., Thornsberry C., Kohrer K., Schmitz F.-J. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:2000;462-466.
7. Jacobs K.A., Rudersdorf R., Neill S.D., Dougherty J.P., Brown E.L., Fritsch E.F. The thermal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium salt solutions: application to identifying recombinant DNA clones. Nucleic Acids Res. 16:1988;4637-4650.
8. Wood W.I., Gitschier J., Lasky L.A., Lawn R.M. Base composition-independent hybridization in tetramethylammonium chloride: a method for oligonucleotide screening of highly complex gene libraries. Proc. Natl. Acad. Sci. USA. 82:1985;1585-1588.
9. Davies T.A., Evangelista A., Pfleger S., Bush K., Sahm D.F., Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46:2002;119-124.
10. Sambrook, J., Fristch, E.F., Maniatas, T. (1989) Molecular Cloning, a laboratory manual. Second ed. Cold Spring Harbor Laboratory Press, New York.